Companies · Biotechnology

Pathos AI, Inc.

CHICAGO · Biotechnology

Diligence memoA one-page analyst read on Pathos AI, Inc. — recommendation, valuation, rhythm, risks.
$365.0M
Total raised · real
3
Rounds
4.6×
Latest step-up
Top 2%
Sector rank · raised
Series D+
Latest stage · inferred · Thu Apr 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Pathos AI, Inc. looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.70× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era.
Active
  • Last raise 14 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Pathos AI, Inc. is one of 4291 Biotechnology companies tracked from CHICAGO. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

ai/ml

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
11
Investors (latest)
2020
Year incorporated
2025-04-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries B · 2023-02-17 Raised $20M (real) Modeled valuation $256M (est)$20M$256MSeries B2023Series C · 2024-10-24 Raised $62M (real) Modeled valuation $490M (est)$62M$490MSeries C2024Series D+ · 2025-04-17 Raised $283M (real) Modeled valuation $2.4B (est)$283M$2.4BSeries D+2025+$62M+$283MCumulative $365M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$20.0M · 2023
Series C$62.0M · 2024
Series D+$283.0M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$2.4B
Base estimate est.
$1.3B
Conservative case
$3.0B
Upside case
$2.4B
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $256.5M · 2023-02-172023Series C · modeled $490.0M · 2024-10-24Series D+ · modeled $2.4B · 2025-04-172025
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
1.2 yr
Elapsed time used
1.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$168.8M/yr
Capital velocity
3.4 yr
On record since
2023
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 51× above median
This company$365.0M
Sector median$7.2M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 2.4× above median
This company$283.0M
Sector median$120.0M
Modeled value — vs sector median (estimate, all stages) 37× above median
This company$2.4B
Sector median$64.2M

Raised more than 99% of sector peers (real $). Modeled value above 95% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 33.

This companyCohort peer
$1.0B$10.0B$100.0M$1.0BCapital raised (log)Kriya Therapeutics, Inc. · Series D+ Raised $870.3M · modeled $2.5B (est)Sensei Biotherapeutics, Inc. · Series D+ Raised $348.9M · modeled $2.2B (est)Odyssey Therapeutics, Inc. · Series D+ Raised $590.9M · modeled $1.7B (est)Rhodenergy An Environmental Co Corp · Series D+ Raised $250.0M · modeled $1.7B (est)Tectonic Therapeutic, Inc. · Series D+ Raised $333.1M · modeled $1.7B (est)Lumicell, Inc. · Series D+ Raised $331.1M · modeled $1.7B (est)MapLight Therapeutics, Inc. · Series D+ Raised $356.2M · modeled $1.5B (est)SAB Biotherapeutics, Inc. · Series D+ Raised $182.5M · modeled $1.4B (est)Immunic, Inc. · Series D+ Raised $514.4M · modeled $1.3B (est)Predictive Oncology Inc. · Series D+ Raised $280.1M · modeled $1.3B (est)Vascular Perfusion Solutions, Inc. · Series D+ Raised $154.9M · modeled $1.2B (est)Pathos AI, Inc. (this company) Raised $365.0M · modeled $2.4B (est)Pathos AI, Inc.
CompanyStageRaised · realValue · estvs peer med.
Kriya Therapeutics, Inc.Series D+$870.3M$2.5B2.79×
Pathos AI, Inc. this companySeries D+$365.0M$2.4B2.70×
Sensei Biotherapeutics, Inc.Series D+$348.9M$2.2B2.53×
Odyssey Therapeutics, Inc.Series D+$590.9M$1.7B1.94×
Rhodenergy An Environmental Co CorpSeries D+$250.0M$1.7B1.89×
Tectonic Therapeutic, Inc.Series D+$333.1M$1.7B1.89×
Lumicell, Inc.Series D+$331.1M$1.7B1.89×
MapLight Therapeutics, Inc.Series D+$356.2M$1.5B1.65×
SAB Biotherapeutics, Inc.Series D+$182.5M$1.4B1.53×
Immunic, Inc.Series D+$514.4M$1.3B1.45×
Predictive Oncology Inc.Series D+$280.1M$1.3B1.42×
Vascular Perfusion Solutions, Inc.Series D+$154.9M$1.2B1.37×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$20.0M2023-02-17$111.1M$256.5M90%
Series C$62.0M2024-10-24$413.3M$490.0M90%
Series D+$283.0M2025-04-17$2.4B$2.4B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$20.0M2023-02-17
    • First recorded raise — entered as Series B.
    • 4 investors on this round.
  2. Series C$62.0M2024-10-24
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 3.1× larger than the prior — scaling up.
    • 13 investors on this round.
  3. Series D+$283.0M2025-04-17
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 4.6× larger than the prior — scaling up.
    • 11 investors on this round.
Intelligence
2026 ~Q2
Modeled next raise · ~13mo cadence
$849.0M
Modeled next size est.range $551.8M$1.4B
4.6×
Last step-up
$168.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Mohamad Makhzoumi9 other2024-10
Eric Lefkofsky7 other2023-02
Tyrell Rivers5 other2025-04
Amit Mehta3 other2024-10
Ryan Fukushima1 other2023-02
Alex Dolan2024-10
Andrew Heinlein2024-10
Eric Lefkofky2024-10
Registry & provenance

Pathos AI, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1967854
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Viela Bio, Inc.BiotechnologySeries D+$357.3M$3.1Bnetwork1 shared operator · same sector · same stage
Tempus Labs, Inc.Software / TechSeries D+$271.0M$178.8Mnetwork2 shared operators · same stage
Reata Pharmaceuticals IncBiotechnologySeries D+$368.9M$2.1Bsame sector · same stage
MapLight Therapeutics, Inc.BiotechnologySeries D+$356.2M$1.5Bsame sector · same stage
Legend Biotech CorpBiotechnologySeries D+$350.5M$3.3Bsame sector · same stage
Carmot Therapeutics Inc.BiotechnologySeries D+$349.8M$2.4Bsame sector · same stage
Cidara Therapeutics, Inc.BiotechnologySeries D+$349.1M$2.8Bsame sector · same stage
Sensei Biotherapeutics, Inc.BiotechnologySeries D+$348.9M$2.2Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Biostate AI, IncBiotechnologySeries A$14.7M88%
Artificial Intelligence Medical Services, Inc.BiotechnologyPre-Seed$797K87%
Bio-AI Health Inc.BiotechnologySeed$2.8M86%
AI Proteins, Inc.BiotechnologySeries A$30.0M86%
NanoSpot.ai, Inc.BiotechnologyPre-Seed$5.2M86%
Genleap Ai Inc.BiotechnologySeries C$1.5B85%
Vitazi.AI, Inc.BiotechnologySeed$1.1M85%
Pathr.ai, Inc.AI / MLSeries A$33.0M84%
Frequently asked
How much funding has Pathos AI, Inc. raised?
Pathos AI, Inc. has raised approximately $365.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Pathos AI, Inc.'s estimated valuation?
Provath's modeled valuation for Pathos AI, Inc. is approximately $2.4B (modeled range $1.3B–$3.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Pathos AI, Inc. at?
Pathos AI, Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Thu Apr 17.
What does Pathos AI, Inc. do and where is it based?
Pathos AI, Inc. operates in the Biotechnology sector, based in CHICAGO.
Explore related

See where Pathos AI, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Pathos AI, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.